


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

AP/1645
26

In re Application of: Yann Echelard et al.



Serial No.: 09/884,586

Art Unit: 1645

Filed: June 19, 2001

Examiner: Quang Nguyen Ph.D.

For: Transgenically Produced Platelet Derived Growth Factor

Atty. Docket No.: GTC-31

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 CFR § § 1.56 and 1.97-1.99, the Applicant cites to the Examiner documents containing information which, in good-faith judgment of the Applicant, may be relevant to the subject matter claimed in the above-identified application. The Applicant also encloses copies of the English-language cited documents.

In submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, or the extent of any search performed, or that more relevant information does not exist.

In submitting this Information Disclosure Statement, the Applicant makes no representation that any document cited in this Information Disclosure Statement is, or is considered to be prior art as defined by 35 USC § § 102 and 103.

A copy of the Supplementary European Search Report from a counterpart application is enclosed. Legible copies of all items listed in Form PTO-1449 accompany this information statement.

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that on December 28, 2004 this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dawn C. Greenaway

I hereby certify that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement. 37 CFR 1.97 (e) (1).

The Applicant respectfully requests that:

- a. The Examiner consider the cited information in reaching a determination concerning the patentability of the pending claims; and
- b. The enclosed Form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.


It is Applicant's understanding that no fee is due; however, if the Applicant is incorrect, please charge any necessary fees for the above-captioned application to Deposit Account No. 502092.

The person making this statement is the attorney who signs below on the basis of the information in the attorney's file.

Respectfully submitted,

Dated: 12/23/04

By:


Byron V. Olsen, Reg. No. 42,960
Attorney for Applicants
175 Crossing Blvd., Suite 410
Framingham, MA 01702
Tel. #(508) 370-5150 Fax #(508) 370-3797

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/884,586
Filing Date	June 19, 2001
First Named Inventor	Yann Echelard
Art Unit	1645
Examiner Name	Quang Nguyen Ph.D.
Attorney Docket Number	GTC-31

Sheet	1	of	2
-------	---	----	---

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]


Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901/04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/884,586
Filing Date	June 19, 2001
First Named Inventor	Yann Echelard
Art Unit	1645
Examiner Name	Quang Nguyen Ph.D.
Attorney Docket Number	GTC-31

Sheet	2	of	2
-------	---	----	---

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Rosen, JM et al., The Mammary Gland as a Bioreactor: Factors Regulating the Efficient Expression of Milk Protein-Based Transgenes, American Journal of Clinical Nutrition, Vol. 63, No. (April 1996)	
		Zinovieva, Natasha et al., Stable production of human insulin-like growth factor 1 (IGF-1) in the milk of hemi-and homozygous transgenic rabbits over several generations, Transgenic Research, Vol. 7, No. 6 (November 1998)	
		Li, J et al., Overexpression of PDGF-A in the lung epithelium of transgenic mice produces a lethal phenotype associated with hyperplasia of mesenchymal cells, Developmental Biology, Vol. 239, no. 2 (November 2001)	

Examiner Signature	Date Considered
-----------------------	--------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901/04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.